Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer

O Otto Metzger (Dana–Farber Cancer Institute, Harvard Medical School, Boston) S Sumithra Mandrekar (Alliance Foundation Trials Statistics and Data Center, Mayo Clinic, Rochester, MN) S Shom Goel (Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia) J Joseph Gligorov E Elgene Lim (Garvan Institute of Medical Research, Sydney) E Eva Ciruelos (Hospital 12 de Octubre, Madrid) S Sibylle Loibl (Johann Wolfgang Goethe Universität, Frankfurt am Main, Germany) T Travis Dockter (Alliance Foundation Trials Statistics and Data Center, Mayo Clinic, Rochester, MN) X Xavier Gonzàlez Farré (Institut Oncològic Dr. Rosell, Hospital General de Catalunya i Quirón Dexeus, Barcelona) P Prudence A. Francis (Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia) F Filipa Lynce (Dana–Farber Cancer Institute, Harvard Medical School, Boston) J Jane Lanzillotti (Alliance Foundation Trials, Boston) C Carter DuFrane (Alliance Foundation Trials, Boston) A Anna Wall (Alliance Foundation Trials Statistics and Data Center, Mayo Clinic, Rochester, MN) C Carrie Strand (Alliance Foundation Trials Statistics and Data Center, Mayo Clinic, Rochester, MN) I Ian Krop (Yale School of Medicine, New Haven, CT) I Ines Vaz-Luis (Cancer Survivorship, INSERM Unité 981, Institut Gustave Roussy, Villejuif, France) D Debu Tripathy (Department of Breast Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA) S Sherene Loi A Aleix Prat M Matthew Goetz S Santiago Escrivá-de-Romaní (Vall d’Hebron Institut of Oncology, Hospital Vall d’Hebron, Barcelona) D David Porter (Auckland District Health Board, Auckland, New Zealand) J Jennifer Spoenlein (Kliniken Essen-Mitte, Essen, Germany) D Daniel G. Stover (Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute, Columbus) S Sagar Sardesai (Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute, Columbus) P Pierre Heudel (Centre Léon Bérard, Lyon, France) M Maria Koehler (Pfizer, Collegeville, PA) C Cynthia Huang Bartlett (Pfizer, New York) A Ariadna Holynskyj (Pfizer, New York) P Prashanth Gopalakrishna (Pfizer, New York) E Eric Gauthier (Pfizer, New York) S Suzette Delaloge K Kathy Miller (Indiana University School of Medicine, Indianapolis) E Eric P. Winer (Yale School of Medicine, New Haven, CT) L Luca Gianni (Fondazione Michelangelo Onlus, Milan) A Ann H. Partridge (Dana–Farber Cancer Institute, Harvard Medical School, Boston) A Angela DeMichele (University of Pennsylvania School of Medicine, Philadelphia) L Lisa A. Carey (Lineberger Comprehensive Cancer Center, UNC Health, Chapel Hill, NC)

Article Details

Volume / Issue Vol. 394, Issue 5
Published January 29, 2026
Pages 451-462
ISSN 0028-4793
Publisher Massachusetts Medical Society

Journal Info

New England Journal of Medicine

Massachusetts Medical Society

ISSN: 0028-4793 Social Sciences

Authors (39)

O

Otto Metzger

Dana–Farber Cancer Institute, Harvard Medical School, Boston

S

Sumithra Mandrekar

Alliance Foundation Trials Statistics and Data Center, Mayo Clinic, Rochester, MN

S

Shom Goel

Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia

J

Joseph Gligorov

E

Elgene Lim

Garvan Institute of Medical Research, Sydney

E

Eva Ciruelos

Hospital 12 de Octubre, Madrid

S

Sibylle Loibl

Johann Wolfgang Goethe Universität, Frankfurt am Main, Germany

T

Travis Dockter

Alliance Foundation Trials Statistics and Data Center, Mayo Clinic, Rochester, MN

X

Xavier Gonzàlez Farré

Institut Oncològic Dr. Rosell, Hospital General de Catalunya i Quirón Dexeus, Barcelona

P

Prudence A. Francis

Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia

F

Filipa Lynce

Dana–Farber Cancer Institute, Harvard Medical School, Boston

J

Jane Lanzillotti

Alliance Foundation Trials, Boston

C

Carter DuFrane

Alliance Foundation Trials, Boston

A

Anna Wall

Alliance Foundation Trials Statistics and Data Center, Mayo Clinic, Rochester, MN

C

Carrie Strand

Alliance Foundation Trials Statistics and Data Center, Mayo Clinic, Rochester, MN

I

Ian Krop

Yale School of Medicine, New Haven, CT

I

Ines Vaz-Luis

Cancer Survivorship, INSERM Unité 981, Institut Gustave Roussy, Villejuif, France

D

Debu Tripathy

Department of Breast Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA

S

Sherene Loi

A

Aleix Prat

M

Matthew Goetz

S

Santiago Escrivá-de-Romaní

Vall d’Hebron Institut of Oncology, Hospital Vall d’Hebron, Barcelona

D

David Porter

Auckland District Health Board, Auckland, New Zealand

J

Jennifer Spoenlein

Kliniken Essen-Mitte, Essen, Germany

D

Daniel G. Stover

Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute, Columbus

S

Sagar Sardesai

Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute, Columbus

P

Pierre Heudel

Centre Léon Bérard, Lyon, France

M

Maria Koehler

Pfizer, Collegeville, PA

C

Cynthia Huang Bartlett

Pfizer, New York

A

Ariadna Holynskyj

Pfizer, New York

P

Prashanth Gopalakrishna

Pfizer, New York

E

Eric Gauthier

Pfizer, New York

S

Suzette Delaloge

K

Kathy Miller

Indiana University School of Medicine, Indianapolis

E

Eric P. Winer

Yale School of Medicine, New Haven, CT

L

Luca Gianni

Fondazione Michelangelo Onlus, Milan

A

Ann H. Partridge

Dana–Farber Cancer Institute, Harvard Medical School, Boston

A

Angela DeMichele

University of Pennsylvania School of Medicine, Philadelphia

L

Lisa A. Carey

Lineberger Comprehensive Cancer Center, UNC Health, Chapel Hill, NC